Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Colorcon
Chinese Patent Office
UBS
Argus Health
Dow
Harvard Business School
Julphar
Cipla

Generated: September 20, 2018

DrugPatentWatch Database Preview

CARBOPLATIN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Carboplatin, and when can generic versions of Carboplatin launch?

Carboplatin is a drug marketed by Cipla Ltd, Fresenius Kabi Usa, Hospira, Mylan Labs Ltd, Pliva, Sandoz, Watson Labs Teva, West-ward Pharms Int, Accord Hlthcare, Actavis Totowa, Akorn, Eugia Pharma, Fresenius Kabi Oncol, Gland Pharma Ltd, Ingenus Pharms Llc, Mylan Institutional, Nanjing King-friend, Pharmachemie Bv, Pliva Lachema, Sandoz Inc, Sun Pharma Global, Teva Parenteral, and Teva Pharms Usa. and is included in thirty-three NDAs.

The generic ingredient in CARBOPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Twelve suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the carboplatin profile page.

Drug patent expirations by year for CARBOPLATIN
Pharmacology for CARBOPLATIN
Medical Subject Heading (MeSH) Categories for CARBOPLATIN
Synonyms for CARBOPLATIN
(SP-4-2)-Diamimine[1,1-cyclobutanedi(carboxylato-kO)(2-)]platinum
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
1,1-Cyclobutanedicarboxylate
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
1,1-CYCLOBUTANEDICARBOXYLATODIAMMINE PLATINUM
1,1-Cyclobutanedicarboxylatodiammineplatinum
1,1-Cyclobutanedicarboxylatodiammineplatinum (II)
1,1-Cyclobutanedicarboxylatodiammineplatinum(II)
10329-EP2269988A2
10329-EP2269989A1
10329-EP2270008A1
10329-EP2272827A1
10329-EP2275102A1
10329-EP2275412A1
10329-EP2275413A1
10329-EP2275420A1
10329-EP2277876A1
10329-EP2280012A2
10329-EP2281815A1
10329-EP2287156A1
10329-EP2292233A2
10329-EP2292614A1
10329-EP2292615A1
10329-EP2292617A1
10329-EP2295055A2
10329-EP2295416A2
10329-EP2295426A1
10329-EP2295427A1
10329-EP2298748A2
10329-EP2298764A1
10329-EP2298765A1
10329-EP2298768A1
10329-EP2298772A1
10329-EP2298778A1
10329-EP2301536A1
10329-EP2301538A1
10329-EP2301928A1
10329-EP2301933A1
10329-EP2305243A1
10329-EP2305640A2
10329-EP2305642A2
10329-EP2305671A1
10329-EP2308812A2
10329-EP2308833A2
10329-EP2308839A1
10329-EP2308855A1
10329-EP2308861A1
10329-EP2311453A1
10329-EP2311455A1
10329-EP2311807A1
10329-EP2311808A1
10329-EP2311825A1
10329-EP2311827A1
10329-EP2311829A1
10329-EP2311840A1
10329-EP2314590A1
10329-EP2316452A1
10329-EP2316831A1
10329-EP2316832A1
10329-EP2316833A1
10329-EP2316834A1
10329-EP2374454A1
41575-94-4
575C944
6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione
6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione diamine
7,7-diamino-[?]spiro[3.5]nonane-5,9-dione
7,7-dimethyl-6,8-dioxa-7$l^{4}-platinaspiro[3.5]nonane-5,9-dione
70903-55-8
AB0013326
AB01273939-01
AB01274771_03
AB01274771-01
AB01274771-02
AB01568249_01
AC-1457
AC1L1DYT
AC1L20N7
AC1NR9YB
AC1O7G18
AK136131
AKOS015905301
AKOS022185820
AKOS024457202
Ambap41575-94-4
AN-265
AOB5507
AS-13313
azane; cyclobutane-1,1-dicarboxylic acid; platinum
BC204693
BDBM50274681
BDBM92389
BG3F62OND5
BSPBio_003145
C 2538
C-21145
C6H10N2O4Pt
C6H6O4Pt.2NH3
Carbopaltin
Carboplatin (JAN/USP/INN)
Carboplatin (JP17/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatin [USAN:USP:INN:BAN:JAN]
Carboplatin, British Pharmacopoeia (BP) Reference Standard
Carboplatin, United States Pharmacopeia (USP) Reference Standard
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Caronplatin, 4
CAS-41575-94-4
Cbdca
cbdca(2-)
CCG-204325
CCG-39887
CCRIS 3404
CHEBI:31355
CHEBI:35690
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cis-Diammine(cyclobutanedicarboxylato)platinumII
cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-diamminecyclobutanedicarboxylatoplatinum(II);
CS-1121
CTK7I5753
cyclobutane dicarboxylate platinum (ii)
cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylate(2-)
cyclobutane-1,1-dicarboxylic acid- platinum(1:1)
cyclobutane-1,1-dicarboxylic acid; platinum
D01363
D0X7HM
DB00958
diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
DivK1c_000892
DR002048
DSSTox_CID_26742
DSSTox_GSID_46742
DSSTox_RID_81870
DTXSID3046742
DVQHYTBCTGYNNN-UHFFFAOYSA-N
EBD50809
EINECS 255-446-0
Epitope ID:194801
Ercar
EU-0100230
FT-0602925
H876
HMS1921J16
HMS2090M05
HMS2092B22
HMS3260N21
HMS3269H03
HMS502M14
HSDB 6957
HY-17393
I14-2390
IDI1_000892
IUPAC: Azane
JM 8
JM-8
K-8751
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac-C-2538
Lopac0_000230
LP00230
LS-117689
MFCD00070464
MolPort-003-845-609
MolPort-006-147-683
MolPort-035-395-692
NCGC00015223-01
NCGC00015223-02
NCGC00015223-03
NCGC00015223-04
NCGC00015223-05
NCGC00015223-06
NCGC00015223-07
NCGC00015223-08
NCGC00015223-09
NCGC00015223-10
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NCGC00260915-01
NCGC00263858-02
NCGC00263858-03
NINDS_000892
NSC 201345
NSC 241240
NSC-201345
NSC-241240
NSC-758182
NSC201345
NSC241240
NSC758182
OLESAACUTLOWQZ-UHFFFAOYSA-L
Paraplatin
Paraplatin (Bristol Meyers)
Paraplatin (TN)
Paraplatin-AQ
Paraplatin, Carboplatin
Pharmakon1600-01502106
Platinum, {diammine[1,1-cyclobut
Platinum, {diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-,} (SP-4-2)-
Platinum, diamine(1, 1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-
Platinum, diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))-, (SP-4-2)-
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-
Platinum, diammine[1,1-cyclobutanedi(carboxylato-.kappa.O)(2-)]-, (SP-4-2)-
Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)-
Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-
Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-
Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-
platinum(+2) cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum(II), (1, 1-cyclobutanedicarboxylato)diammine-, cis-
Platinum(II), (1,1-cyclobutanedicarboxylato)diammine-, cis-
Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis-
RL03611
s1215
SBI-0050218.P002
SC-18620
SCHEMBL2671349
SCHEMBL4964
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
SR-01000076253
SR-01000076253-5
ST24046284
STL451040
Tox21_112586
Tox21_112586_1
Tox21_500230
UNII-BG3F62OND5
W-106301
ZB013490

US Patents and Regulatory Information for CARBOPLATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Labs Ltd CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 091063-003 Nov 9, 2011 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Usa CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 077139-004 Sep 21, 2005 AP RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Eugia Pharma CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 205487-001 Mar 28, 2016 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Actavis Totowa CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 078732-004 Feb 6, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pliva Lachema CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 078631-002 Dec 2, 2008 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Kabi Usa CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 077247-002 Oct 21, 2004 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira CARBOPLATIN carboplatin INJECTABLE;IV (INFUSION) 076517-003 Oct 14, 2004 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Colorcon
Chinese Patent Office
UBS
Argus Health
Dow
Harvard Business School
Julphar
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.